Insider Selling: Beta Bionics (NASDAQ:BBNX) Insider Sells 30,779 Shares

Beta Bionics, Inc. (NASDAQ:BBNX) insider Mark Hopman sold 30,779 shares of the stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $20.13, for a total value of $619,581.27. Following the completion of the transaction, the insider directly owned 56,479 shares of the company’s stock, valued at approximately $1,136,922.27. The trade was a 35.27% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Mark Hopman also recently made the following trade(s):

• On Wednesday, September 9th, Mark Hopman sold 36,870 shares of Beta Bionics stock. The shares were sold at an average price of $18.46, for a total transaction of $680,620.20.
• On Wednesday, September 2nd, Mark Hopman sold 5,327 shares of Beta Bionics stock. The stock was sold at an average price of $19.11, for a total transaction of $101,798.97.
• On Wednesday, June 24th, Mark Hopman sold 1,258 shares of Beta Bionics stock. The shares were sold at an average price of $15.01, for a total transaction of $18,882.58.

Beta Bionics Stock Down 3.4%

Beta Bionics stock traded down $0.75 during trading hours on Thursday, hitting $21.43. 3,089,176 shares of the company traded hands, compared to its average volume of 1,193,079. The firm has a market cap of $964.14 million, a P/E ratio of -12.99 and a beta of 3.37. The firm’s 50-day simple moving average is $17.46 and its two-hundred day simple moving average is $13.93. Beta Bionics, Inc. has a 1-year low of $8.80 and a 1-year high of $32.71.

Beta Bionics (NASDAQ:BBNX) last issued its quarterly earnings results on Wednesday, July 29th. The company reported ($0.53) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.62) by $0.09. The company had revenue of $32.01 million during the quarter. Beta Bionics had a negative net margin of 61.31% and a negative return on equity of 26.30%. On average, equities research analysts predict that Beta Bionics, Inc. will post -2.05 earnings per share for the current year.

Trending Headlines about Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: The U.S. FDA cleared Beta Bionics’ Mint patch pump, expanding the company’s diabetes-device portfolio beyond the iLet Bionic Pancreas. A full U.S. launch is planned for the first quarter of 2027, creating a potential additional growth driver. Beta Bionics Stock Surges on FDA Clearance for Mint Patch Pump
• Positive Sentiment: Analysts and market coverage have highlighted the Mint clearance as a step toward a broader, multi-product growth strategy. Recent earnings-estimate trends and a price-target increase from Bank of America also supported buying interest. Beta Bionics Shares Rise After BofA Price-Target Boost
• Positive Sentiment: Beta Bionics priced a public offering expected to raise approximately $150 million. The proceeds could fund Mint commercialization, manufacturing expansion, research and development, and working capital, improving financial flexibility. Beta Bionics Announces Pricing of Public Offering
• Neutral Sentiment: The offering includes 7.65 million common shares and pre-funded warrants for approximately 1.04 million additional shares, with a potential underwriters’ option for 1.30 million more shares. The capital raise strengthens the balance sheet but increases the potential share count.
• Negative Sentiment: Multiple law firms are publicizing a securities class action against Beta Bionics. The litigation alleges that management understated the significance of FDA Form 483 findings, a subsequent warning letter, quality-management issues, and unreported customer complaints. Investors have until November 3, 2026, to seek lead-plaintiff status; the allegations have not been proven. BBNX Shareholder Alert
• Negative Sentiment: Beta Bionics’ updated 2026 revenue outlook of $121 million to $126 million is below the roughly $133.9 million consensus estimate, raising concerns about near-term execution and commercialization. The equity offering may also weigh on the stock through dilution.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in BBNX. BlackRock Inc. purchased a new stake in shares of Beta Bionics during the second quarter valued at $52,340,000. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in Beta Bionics in the 4th quarter worth about $40,437,000. Eversept Partners LP raised its holdings in Beta Bionics by 108.6% during the 1st quarter. Eversept Partners LP now owns 1,414,838 shares of the company’s stock worth $14,177,000 after buying an additional 736,576 shares during the period. 12 West Capital Management LP acquired a new stake in Beta Bionics during the 4th quarter worth about $17,520,000. Finally, Bruce & Co. Inc. purchased a new stake in Beta Bionics during the first quarter valued at about $5,518,000.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Truist Financial reaffirmed a “buy” rating and set a $23.00 price target (up from $22.00) on shares of Beta Bionics in a research note on Tuesday. The Goldman Sachs Group boosted their price objective on Beta Bionics from $17.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. UBS Group restated a “buy” rating and issued a $25.00 price objective on shares of Beta Bionics in a report on Tuesday. William Blair assumed coverage on Beta Bionics in a research note on Friday, August 21st. They set a “market perform” rating for the company. Finally, Leerink Partners lifted their target price on Beta Bionics from $24.00 to $27.00 and gave the stock an “outperform” rating in a report on Monday. Seven analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $21.90.

Beta Bionics Company Profile

Beta Bionics, Inc is a medical technology company focused on developing automated insulin-delivery systems for people with diabetes. Its principal product is the iLet Bionic Pancreas, an automated insulin-delivery system designed to simplify diabetes management by using continuous glucose monitoring data to adjust insulin dosing with limited user input.

The iLet Bionic Pancreas received clearance from the U.S. Food and Drug Administration in 2023 for use by people with type 1 diabetes.